Drug Lifecycle Phase

Continuous Benefit-Risk Monitoring for Marketed Products

Automated PSUR/PBRER generation, signal management, and RMP updates — grounded in 100+ billion data points of real-world evidence. At this critical stage, continuous benefit-risk monitoring ensures ongoing compliance, early signal detection, and proactive risk management for marketed products across global markets.

Request Post-Marketing Demo

Drug Development Lifecycle

Where Post-Marketing Sits in the Drug Development Journey

1

Preclinical & Phase I

Early safety signals

2

Phase II

Dose finding & efficacy

3

Phase III

Confirmatory trials

4

Regulatory Submission

NDA/BLA/MAA filing

5

Post-Marketing

Continuous surveillance

6

Market Access & HTA

Reimbursement & value

Key Challenges

Benefit-Risk Analysis Challenges at Post-Marketing

Each development phase brings unique benefit-risk assessment challenges. Here's what pharmaceutical teams face during Post-Marketing Surveillance.

PSUR/PBRER Production Cycle Times

Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) are required at defined intervals—often annually or semi-annually—for all marketed products. Manual production consumes weeks of medical writer and pharmacovigilance specialist time per product. Large portfolios with staggered PSUR cycles create continuous workload peaks. The ICH E2C(R2) format requires comprehensive sections on signal evaluation, benefit-risk re-assessment, and conclusions—all of which must be regenerated from evolving data for each reporting period.

Growing Spontaneous Reporting Volumes

Spontaneous adverse event reporting continues to grow as products reach broader patient populations and reporting systems become more accessible. High-volume products can accumulate thousands of case reports per quarter. Signal detection must operate at scale, distinguishing true signals from noise, duplicate reports, and reporting artifacts. Manual case review and signal triage cannot keep pace with incoming volumes, creating risk that important signals are detected late or missed entirely until regulatory authorities flag them during inspection.

Risk Management Plan Maintenance

RMPs are living documents that must be updated as new safety information emerges. Changes to the safety specification, pharmacovigilance plan, or risk minimization measures require RMP amendments submitted to EMA and other authorities. Each amendment must demonstrate that benefit-risk conclusions remain favorable despite new safety findings. Maintaining RMP consistency with evolving PSURs, label changes, and signal assessment reports across multiple markets (EU, UK, Japan, Canada) is complex and error-prone when managed manually.

Multi-Product, Multi-Market Complexity

Large pharmaceutical companies manage dozens of marketed products across 50+ countries, each with different PSUR schedules, RMP requirements, and regulatory timelines. A single product may have overlapping PSUR cycles in different regions (EU annual, US 6-month). Coordinating safety data collection, signal assessment, benefit-risk evaluation, and document production across this matrix of products and markets requires sophisticated workflow management. Manual processes create bottlenecks where pharmacovigilance teams become overwhelmed by administrative burden rather than focusing on scientific signal assessment.

ArcaScience for Post-Marketing

How the Platform Addresses Post-Marketing BRA Challenges

ArcaScience's three integrated modules provide end-to-end benefit-risk analysis capabilities specifically tailored to Post-Marketing Surveillance requirements.

Data Intelligence

Data Intelligence for Post-Marketing

Continuous data feeds from FAERS, EudraVigilance, VigiBase, published literature, and internal safety databases enable real-time signal detection. Automated deduplication, case narrative extraction, and MedDRA coding normalization process thousands of reports daily. Integration with real-world evidence provides background rate context to distinguish true signals from expected adverse event rates in target populations.

  • Continuous signal detection across FAERS, EudraVigilance, VigiBase
  • Automated case report processing and MedDRA coding
  • Real-world evidence for background rate contextualization
Explore Data Engine →
Decision Intelligence

Decision Intelligence for Post-Marketing

Disproportionality analysis (PRR, ROR, IC) and temporal pattern detection algorithms operate continuously on incoming spontaneous reports. Signal triage prioritizes clinically significant findings for human review. Benefit-risk re-evaluation frameworks apply BRAT and MCDA methodologies to assess whether new safety findings alter the overall benefit-risk balance established at approval.

  • Automated signal detection with disproportionality analysis
  • Continuous benefit-risk re-evaluation with BRAT framework
  • RMP update triggers based on emerging safety data
Explore Decision Engine →
Automated Outputs

Regulatory Outputs for Post-Marketing

Automated PSUR/PBRER generation aligned with ICH E2C(R2) produces submission-ready documents in days rather than weeks. Signal detection reports include case line listings, statistical analyses, and clinical assessments. RMP updates maintain consistency with PSURs and label changes across all markets. Lifecycle continuity ensures that the benefit-risk framework established during development carries forward into post-marketing surveillance.

  • Automated PSUR/PBRER generation per ICH E2C(R2)
  • Signal detection and assessment reports with case line listings
  • RMP updates synchronized with evolving safety data
Explore Outputs →

Deliverables

Typical Outputs for Post-Marketing Surveillance

ArcaScience generates regulatory-ready deliverables tailored to post-marketing surveillance and pharmacovigilance requirements.

PSUR/PBRER Documents

ICH E2C(R2)-compliant Periodic Safety Update Reports and Periodic Benefit-Risk Evaluation Reports generated from continuous surveillance data.

Signal Detection and Assessment Reports

Comprehensive signal reports with disproportionality analyses, case line listings, clinical assessment, and benefit-risk impact evaluation.

RMP Updates and Amendments

Risk Management Plan updates triggered by emerging safety data, maintaining consistency with PSURs and label changes across markets.

Benefit-Risk Re-Evaluation Documents

Periodic benefit-risk re-assessments demonstrating that marketed products maintain favorable benefit-risk balance as new evidence emerges.

Regulatory Authority Response Documents

Responses to EMA PRAC, FDA inquiries, and PMDA consultations with quantitative benefit-risk frameworks supporting regulatory positions.

Multi-Country PSUR Harmonization

Harmonized PSURs across 47+ countries with region-specific formatting while maintaining consistent benefit-risk conclusions.

Regulatory Context

What Regulators Expect for Post-Marketing Surveillance

Understanding regulatory authority expectations for continuous benefit-risk monitoring is critical for maintaining compliance and market authorization.

FDA's post-marketing surveillance expectations emphasize continuous signal detection, timely reporting of serious adverse events, and periodic benefit-risk re-evaluation. PBRER requirements (adopted from ICH E2C(R2)) mandate comprehensive benefit-risk assessment sections that integrate cumulative safety data with ongoing efficacy monitoring. FDA inspections assess pharmacovigilance systems for signal detection capabilities, case processing timeliness, and benefit-risk re-evaluation rigor. ArcaScience's continuous surveillance and automated PBRER generation ensure FDA compliance while reducing pharmacovigilance workload.

Key FDA Guidance:

  • Periodic Benefit-Risk Evaluation Report (ICH E2C(R2) US Implementation, December 2016)
  • FDA Adverse Event Reporting System (FAERS) Reporting Requirements

EMA's PSUR requirements (GVP Module VII) mandate comprehensive periodic safety update reports with integrated benefit-risk evaluation sections. The Pharmacovigilance Risk Assessment Committee (PRAC) reviews PSURs and assesses whether new safety findings require RMP updates, label changes, or regulatory action. EMA emphasizes signal management (GVP Module IX) with expectations for continuous monitoring, rapid signal detection, and thorough signal validation. The platform's automated PSUR generation and RMP update capabilities ensure EMA GVP compliance across all modules.

Key EMA Guidance:

  • Guideline on Good Pharmacovigilance Practices (GVP) – Module VII: Periodic Safety Update Report (Rev 1)
  • GVP Module IX: Signal Management (Rev 1)

PMDA's post-marketing surveillance requirements emphasize re-examination and re-evaluation periods for new drugs, during which intensive safety monitoring is mandated. J-RMPs must be updated as new safety information emerges, with particular attention to adverse events observed in Japanese patients. PMDA expects timely reporting of serious adverse events and comprehensive periodic reports that address whether the benefit-risk profile observed in clinical trials is maintained in real-world Japanese clinical practice. The platform's J-RMP update automation and Japanese population analytics support PMDA's post-marketing surveillance expectations.

Key PMDA Guidance:

  • Ordinance on Standards for Conducting Post-Marketing Surveillance and Studies (MHLW Ordinance No. 171, 2004)
  • Guideline on Risk Management Plan (Yakushokuhatsu 0430 No. 1)

Post-Marketing Case Study

Sanofi: 60% Reduction in PSUR Cycle Time Across 47 Countries

Sanofi's global pharmacovigilance team managed PSURs for a mature diabetes portfolio across 47 countries with staggered reporting cycles. Manual PSUR production consumed 4-6 weeks per product per reporting period, with medical writers spending 60% of their time on administrative tasks rather than scientific signal assessment. The team faced growing pressure from increasing spontaneous reporting volumes and EMA's push for more comprehensive benefit-risk evaluation sections.

ArcaScience's platform automated PSUR generation from continuous surveillance data feeds, reducing cycle time from 6 weeks to 2.5 weeks—a 60% improvement. Signal detection algorithms processed incoming FAERS and EudraVigilance reports continuously, flagging clinically significant signals for human review. Harmonized PSURs maintained consistent benefit-risk conclusions across all 47 countries while respecting region-specific formatting requirements. Medical writers reallocated time to high-value scientific assessment rather than document production, improving signal detection quality and reducing regulatory risk.

60%

Reduction in PSUR cycle time

47

Countries harmonized

Read Full Case Study →

"ArcaScience transformed our PSUR production process. We cut cycle time from 6 weeks to 2.5 weeks per product, allowing our medical writers to focus on scientific signal assessment rather than document formatting. The platform's continuous surveillance and automated signal detection gave us confidence that we're identifying safety signals earlier than ever before. Harmonizing PSURs across 47 countries while maintaining regulatory compliance would have been impossible with manual processes."

Dr. Jean-Pierre Dubois

Global Head of Pharmacovigilance

Sanofi — Diabetes Portfolio

120

Marketed products monitored

Lifecycle Navigation

Explore Adjacent Development Phases

Previous Phase

Regulatory Submission

Next Phase

Market Access & HTA
View All Lifecycle Phases →

See ArcaScience Applied to Post-Marketing Surveillance

Request a demonstration customized to your post-marketing needs. Our scientists will show you how the platform ingests continuous surveillance data, applies signal detection algorithms, and generates regulatory-ready PSURs and RMP updates.

Discuss Your Post-Marketing Needs Explore the Platform →